Results 111 to 120 of about 22,552 (237)

Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination

open access: yes, 2000
BACKGROUND: Lupus anticoagulant (antiphospholipid antibodies) is associated with venous and arterial thrombosis in patients with and without autoimmune disorders. Vitamin K antagonists are the treatment of choice in patients with thrombosis, of which the
Bijsterveld, N. R.   +3 more
core   +1 more source

Immune endotypes in tuberculosis: Keys to decoding disease complexity

open access: yesJournal of Internal Medicine, Volume 299, Issue 6, Page 670-693, June 2026.
Abstract Tuberculosis (TB) remains a major global health challenge, with multi‐drug antibiotic regimens as the current standard of care. While effective at killing Mycobacterium tuberculosis, these treatments do not resolve persistent inflammation, prevent lung damage, or reverse immune dysregulation that contribute to poor outcomes and disease ...
Shamila D. Alipoor   +4 more
wiley   +1 more source

Pulmonary haemorrhage, pulmonary infarction, and the lupus anticoagulant

open access: yes, 1988
SUMMARY A patient with systemic lupus erythematosus developed pulmonary haemorrhage and pulmonary infarction as rare initial manifestations of her disease. The latter was associated with the presence of the circulating lupus anticoagulant.
P H Feng, H S Howe, M L Boey, K Y Fong
core  

Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing

open access: yes, 2005
Interlaboratory and intermethod variation in commercial and in-house tests used for the measurement of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) limit the diagnostic value of the results from these tests.
Gillis, David   +3 more
core   +1 more source

Síndrome antifosfolipídico catastrófico [PDF]

open access: yes, 2006
[spa] INTRODUCCIÓN: El síndrome antifosfolipídico catastrófico fue descrito por Asherson en el año 1992 como una variante del síndrome antifosfolipídico (SAF) que conduce a insuficiencia multiorgánica, caracteriza por la oclusión trombótica de los vasos ...
Bucciarelli, Silvia
core  

Lupus Anticoagulant Positivity in Autoimmune Thyroid Diseases

open access: yesEndocrinology Research and Practice, 2008
Objective: Autoimmune thyroid diseases are often concomitant with the other autoimmune diseases. In this study, our aim was to assess the presence of lupus anticoagulant, which is an antibody involved in the etiology of thrombosis, in patients with ...
Meftun Çelikci   +5 more
doaj   +2 more sources

Bleeding and Thrombosis in a Patient with Secondary Antiphospholipid Syndrome

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2008
Antiphospholipid antibodies have been associated with occurrence of arterial and venous thrombotic events and fetal loss, which together constitute the antiphospholipid syndrome (APS). However, bleeding is rare in this syndrome.
Kaaroud Hayet   +8 more
doaj  

An improved method for lupus anticoagulant detection

open access: yes, 2005
The diagnosis of lupus anticoagulant (LA) becomes difficult when there is a weak titer of LA antibodies. This study demonstrates that 20 minutes' incubation increases the sensitivity of the mixing test to diagnose LA by 23% and to suspect: the antibodies
Efira, André   +5 more
core  

Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection

open access: yes, 2000
Acquired protein S deficiency and lupus anticoagulant have been described in children with varicella who had pul-pura fulminans. disseminated intravascular coagulation or thrombosis.
Vardar, F   +4 more
core   +1 more source

Thrombembolic events in patients with non-hodgkin's lymphoma And anticardiolipin antibodies

open access: yesHematology Reports, 2020
Patients with non-Hodgkin's lymphoma (NHL) have an increased risk of thromboembolic events. It is important to identify NHL patients at increased risk of developing thromboembolic complications in order to apply prophylactic treatment.
S. Buruiana   +3 more
doaj  

Home - About - Disclaimer - Privacy